The findings will allow researchers to compare infections and symptoms among people who are currently vaccinated and who get one dose or two doses of the Omicron shot. They will be compared with those who have been boosted with the current vaccine and receive a dose of the Omicron vaccine.
The data from the American pharmaceutical giant and the German biotechnology company will help scientists and public health experts to learn more about the benefits of variant-specific vaccines. This will also determine if variant-specific vaccines will be necessary going forward.
Key takeaways
Pfizer and BioNTech are developing a vaccine specifically to combat the COVID-19 Omicron variant. The Omicron variant has quickly become the dominant coronavirus strain. Current vaccines and boosters in the market are the first line of defense against the coronavirus. The spike in COVID-19 cases in the Philippines has coincided with the rise of Omicron globally. A number of reasons have been given for the development of Pfizer BioNTech vaccine against Omicron. One reason is to determine if variant-specific vaccines will be necessary from now on.
For more on coronavirus, click here.
Comments
Share your thoughts
Be the first to let Hello Doctor know your thoughts!
Join Us or Log In to join the discussion